Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 8/20 | 0.48 |
| ▸ | CES2 | O00748 | 7/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108642 | 0.68 | CES1 (1.00) | CES1CES2HDAC3HDAC1HDAC2 | |
| SCHEMBL8644662 | 0.67 | ALDH1A1 (0.33) | TSHRALDH1A1 | |
| SCHEMBL5553526 | 0.67 | CES1 (0.46) | CES1CES2HDAC3HDAC1HDAC2 | |
| SCHEMBL18691971 | 0.65 | TDP1 (0.30) | — | |
| SCHEMBL6650435 | 0.65 | CES1 (0.58) | CES1CES2HDAC3HDAC1HDAC2 | |
| SCHEMBL1462669 | 0.64 | CES2 (0.63) | CES1CES2HDAC3HDAC1HDAC2 | |
| SCHEMBL16940468 | 0.64 | CES1 (0.63) | CES1CES2HDAC3HDAC1HDAC2 | |
| SCHEMBL10936238 | 0.63 | CES1 (0.73) | CES1CES2HDAC3HDAC1HDAC2 | |
| SCHEMBL10532393 | 0.63 | ALDH1A1 (0.32) | TSHRALDH1A1 | |
| SCHEMBL6309457 | 0.62 | ALDH1A1 (0.46) | CES1CES2HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026349-B2 | Polynucleotide synthesis labeling chemistry | DHARMACON, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20080009612-A1 | Novel Polynucleotide Synthesis Labeling Chemistry | DHARMACON, INC. | 2008-01-10 | — | — | US | disclosed |
| EP-1788875-A2 | NOVEL POLYNUCLEOTIDE SYNTHESIS LABELING CHEMISTRY | Dharmacon, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006033730-A2 | NOVEL POLYNUCLEOTIDE SYNTHESIS LABELING CHEMISTRY | DHARMACON, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009612-A1 | Novel Polynucleotide Synthesis Labeling Chemistry | POLN, POLRMT, POLM | CES1 3311/4885CES2 1341/4885HDAC3 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.